ESC 2023 focused update: heart failure
International ESC Current
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh TA, et al. Eur Heart J. 2023;44:3627–3639
DOI 10.1093/eurheartj/ehad195 · Summary checked against the source: 2026-11
This update changes specific parts of ESC 2021 in light of trials published after it, including EMPEROR-Preserved, DELIVER, STRONG-HF, FIDELIO-DKD and EMPA-KIDNEY. Everything not listed here stays as in the 2021 guideline.
What changed
| Topic | 2021 | 2023 |
|---|---|---|
| SGLT2i in HFmrEF | No recommendation | I, A |
| SGLT2i in HFpEF | No recommendation | I, A |
| After an HF admission | – | Intensive GDMT start and up-titration before discharge and over 6 weeks: I, B |
| T2DM + CKD (preventing HF) | – | SGLT2i: I, A · finerenone: I, A |
| IV iron for symptoms (HFrEF/HFmrEF) | IIa, A | I, A |
| IV iron to cut HF hospitalisation | IIa, B | IIa, A (ferric carboxymaltose or ferric derisomaltose) |
HFmrEF and HFpEF
- SGLT2 inhibitor (dapagliflozin or empagliflozin) in symptomatic HFmrEF and in symptomatic HFpEF, to reduce HF hospitalisation or CV death.
The evidence comes from the primary composite endpoint of EMPEROR-Preserved and DELIVER. The benefit was only in HF hospitalisation; CV death didn't fall.
flowchart TD
A["Management of HFmrEF"] --> D["Diuretics for fluid retention<br/>Class I"]
A --> S["Dapagliflozin / empagliflozin<br/>Class I"]
A --> R["ACE-I / ARNI / ARB<br/>Class IIb"]
A --> M["MRA<br/>Class IIb"]
A --> B["Beta-blocker<br/>Class IIb"]
Adapted from ESC 2023 Figure 1 [p. 3633]
flowchart TD
A["Management of HFpEF"] --> D["Diuretics for fluid retention<br/>Class I"]
A --> S["Dapagliflozin / empagliflozin<br/>Class I"]
A --> C["Treat the cause, and CV and<br/>non-CV comorbidities<br/>Class I"]
Adapted from ESC 2023 Figure 2 [p. 3633]
Before and after discharge
- An intensive strategy: start evidence-based drugs and up-titrate them quickly before discharge and at frequent follow-up visits in the first 6 weeks after an HF admission. This reduces HF rehospitalisation or death.
In STRONG-HF this meant ACE-I/ARB/ARNI, beta-blockers and MRA, across HFrEF, HFmrEF and HFpEF. Only HF rehospitalisation fell; CV and all-cause death didn't.
Preventing HF in type 2 diabetes with CKD
- SGLT2 inhibitors to reduce HF hospitalisation or CV death.
- Finerenone to reduce HF hospitalisation.
CKD here follows the trial definitions (DAPA-CKD, EMPA-KIDNEY, FIDELIO-DKD and others): broadly eGFR 20–90 mL/min/1.73 m² with a raised urine albumin-to-creatinine ratio.
Iron deficiency
- IV iron in symptomatic HFrEF and HFmrEF with iron deficiency, to relieve symptoms and improve quality of life.
- IV ferric carboxymaltose or ferric derisomaltose in symptomatic HFrEF and HFmrEF with iron deficiency, to reduce HF hospitalisation.
Most of the evidence is from patients with LVEF ≤45%. Iron deficiency is defined as in 2021: ferritin <100 ng/mL, or 100–299 ng/mL with TSAT <20%.
Clinical pearls
- After 2023, SGLT2 inhibitors are Class I at every LVEF in ESC (HFrEF, HFmrEF, HFpEF).
- In HFmrEF and HFpEF, SGLT2i reduce HF hospitalisation, not CV death.
- STRONG-HF: fast up-titration within 6 weeks of discharge.
- Finerenone (a non-steroidal MRA) is for T2DM with CKD, to prevent HF.
Classes and levels of evidence
How ESC 2023 focused update grades its recommendations. Adapted from ESC 2023 focused update Tables 1 and 2 [p. 3630]. Hover over any class or level cited on this page to see what it means.
| Class | Meaning | Wording used |
|---|---|---|
| Class I | Evidence and/or general agreement that a treatment or procedure is beneficial, useful and effective | is recommended or is indicated |
| Class IIa | Weight of evidence or opinion is in favour of usefulness or efficacy | should be considered |
| Class IIb | Usefulness or efficacy is less well established by evidence or opinion | may be considered |
| Class III | Evidence or general agreement that the treatment or procedure isn't useful or effective, and in some cases may be harmful | is not recommended |
| Level | Meaning |
|---|---|
| Level A | Data from multiple randomised clinical trials or meta-analyses |
| Level B | Data from a single randomised clinical trial or large non-randomised studies |
| Level C | Consensus of expert opinion and/or small studies, retrospective studies, registries |
Class II covers conflicting evidence or a divergence of opinion about usefulness or efficacy. It's split into IIa and IIb.